Case Study #2: Why Waiting Is Better For Advanced Life Sciences
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
While companies like Replidyne and Sanofi-Aventis have been caught in the evolving regulatory standards for non-inferiority trial design in antibiotics, one firm has elected to wait for further clarification before submitting a new drug application.